vers la météo de la validation par utilisateur
+---------------------SUBJ:V-N--------------------+ | +--------COMP:N-N(of)-------+ | +-------OBJ:V-N-------+ | | +-MOD_ATT:N-ADJ-+ +-----------COMP:V-V(to)-----------+ +-MOD_ATT:N-ADJ-+ +----APPOS----+ | +MOD_ATT+ +COMP:V-N(in+ | | +MOD_ATT:+ | | | | | | | | | | | __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase III clinical trial to treat acute myeloid leukemia . APPOS (__NODE__,inhibiter) COMP:N-N(of) (inhibiter,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) SUBJ:V-N (be,__NODE__) COMP:V-N(in) (be,III) COMP:V-V(to) (be,treat) OBJ:V-N (treat,leukemia) MOD_ATT:N-ADJ (leukemia,acute) MOD_ATT:N-ADJ (leukemia,myeloid)
+---------------------SUBJ:V-N--------------------+----------------------COMP:V-N(to)----------------------+ | +--------COMP:N-N(of)-------+ | +-----MOD_ATT:N-N-----+ | | +-MOD_ATT:N-ADJ-+ | | +-MOD_ATT:N-ADJ-+ +----APPOS----+ | +MOD_ATT+ +COMP:V-N(in+ | | +MOD_ATT:+ | | | | | | | | | | | __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase III clinical trial to treat acute myeloid leukemia . APPOS (__NODE__,inhibiter) COMP:N-N(of) (inhibiter,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) SUBJ:V-N (be,__NODE__) COMP:V-N(in) (be,III) COMP:V-N(to) (be,leukemia) MOD_ATT:N-N (leukemia,treat) MOD_ATT:N-ADJ (leukemia,acute) MOD_ATT:N-ADJ (leukemia,myeloid)
+----------------------COMP:V-N(in)----------------------+ | +-----------------MOD_ATT:N-N----------------+ +---------------------SUBJ:V-N--------------------+ | +----------MOD_ATT:N-N---------+ | +--------COMP:N-N(of)-------+ | | | +-----MOD_ATT:N-N-----+ | | +-MOD_ATT:N-ADJ-+ | | | | +-MOD_ATT:N-ADJ-+ +----APPOS----+ | +MOD_ATT+ | | | | | +MOD_ATT:+ | | | | | | | | | | | | __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase III clinical trial to treat acute myeloid leukemia . APPOS (__NODE__,inhibiter) COMP:N-N(of) (inhibiter,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) SUBJ:V-N (be,__NODE__) COMP:V-N(in) (be,leukemia) MOD_ATT:N-N (leukemia,III) MOD_ATT:N-N (leukemia,trial) MOD_ATT:N-N (leukemia,treat) MOD_ATT:N-ADJ (leukemia,acute) MOD_ATT:N-ADJ (leukemia,myeloid)
+----------------------COMP:V-N(in)----------------------+ | +-------------------MOD_ATT:N-N-------------------+ | | +-----------------MOD_ATT:N-N----------------+ +---------------------SUBJ:V-N--------------------+ | | +----------MOD_ATT:N-N---------+ | +--------COMP:N-N(of)-------+ | | | | +-----MOD_ATT:N-N-----+ | | +-MOD_ATT:N-ADJ-+ | | | | | +-MOD_ATT:N-ADJ-+ +----APPOS----+ | +MOD_ATT+ | | | | | | +MOD_ATT:+ | | | | | | | | | | | | | __NODE__ , an inhibitor of __SP__ __NODE__ protein , is in Phase III clinical trial to treat acute myeloid leukemia . APPOS (__NODE__,inhibiter) COMP:N-N(of) (inhibiter,protein) MOD_ATT:N-ADJ (protein,__SP__) MOD_ATT:N-ADJ (protein,__NODE__) SUBJ:V-N (be,__NODE__) COMP:V-N(in) (be,leukemia) MOD_ATT:N-N (leukemia,phase) MOD_ATT:N-N (leukemia,III) MOD_ATT:N-N (leukemia,trial) MOD_ATT:N-N (leukemia,treat) MOD_ATT:N-ADJ (leukemia,acute) MOD_ATT:N-ADJ (leukemia,myeloid)